½ÉÀå´ë»çÁõÈıºÇÐȸ 2021 Ãß°è½ÉÆ÷Áö¾ö : 2021-09-25±³À°ÀÏÀÚ : 2021-09-25
±³À°Àå¼Ò : ½ºÀ§½º±×·£µåÈ£ÅÚ Flamingo Room
±³À°ÁÖÁ¦ :
½ÉÀå´ë»çÁõÈıºÇÐȸ 2021 Ãß°è½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÉÀå´ë»çÁõÈıºÇÐȸ
´ã´çÀÚ : ¿À¼öÇö
¿¬¶ôó : 032-460-0000
À̸ÞÀÏ :
apcms@kscms.org ±³À°Á¾·ù : ³»°ú¿¹¹æÀÇÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀοø : 70¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ±³¼ö ¹× °³¿øÀÇ 4¸¸¿ø / Àü°øÀÇ, ÀüÀÓÀÇ, ±âŸ 2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-25 Flamingo 09:00~09:15 TG variability ¹Ú»ó¹Î(À»ÁöÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 09-25 Flamingo 09:15~09:30 BP variability ±èÇзÉ(¼¿ïÀÇ´ë º¸¶ó¸Åº´¿ø ¼øȯ±â³»°ú)
±³À°½Ã°£ 09-25 Flamingo 09:30~09:45 Glucose variability ¿ÀÅÂÁ¤(ºÐ´ç¼¿ï´ë ¼øȯ±â³»°ú)
Åä·Ð 09-25 Flamingo 09:45~10:05 Discussion All Panellist()
ÈÞ½Ä 09-25 Flamingo 10:05~10:45 Coffee Break & Photo Time ()
±³À°½Ã°£ 09-25 Flamingo 10:45~11:00 µðÁöÅÐÇコ_ ÆÐÄ¡Çü 12-Àü±Ø ½ÉÀüµµ È°¿ë Â÷¿øö(»ï¼º¼¿ïº´¿ø ÀÀ±ÞÀÇÇаú)
±³À°½Ã°£ 09-25 Flamingo 11:00~11:15 µðÁöÅÐÇコ_ »ýü½ÅÈ£ ±â¹Ý, ÀΰøÁö´É CDSS À±´ö¿ë(¿¬¼¼´ëÇб³ ÀÇ»ý¸í½Ã½ºÅÛÁ¤º¸Çб³½Ç)
±³À°½Ã°£ 09-25 Flamingo 11:15~11:30 ºñ´ë¸éÁø·á_ ±Ù°Å ±â¹ÝÀÇ ÀÓ»óÈ°¿ë ±èÇ强(°¡Å縯´ëÇб³ ÀÇ·áÁ¤º¸Çб³½Ç ¼¿ï¼º¸ðº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09-25 Flamingo 11:30~11:45 ºñ´ë¸éÁø·á_ ÀÓ»óÈ°¿ë »ç·Êº° ¹ýÀû ÀïÁ¡ À¯ÁöÇö(¹ý¹«¹ýÀÎ ±¤Àå)
Åä·Ð 09-25 Flamingo 11:45~12:05 Discussion All Panellist()
±³À°½Ã°£ 09-25 Flamingo 12:05~12:20 Are all statins the same? ÃÖö¿õ(°í´ë±¸·Îº´¿ø ¼øȯ±â³»°ú)
±³À°½Ã°£ 09-25 Flamingo 12:20~12:35 Sevikar HCT, Who Will Benefit From It? ¹®Á¤±Ù(°¡ÃµÀÇ´ë ½ÉÀå³»°ú)
½Ä»ç 09-25 Triangle Foyer 12:35~13:35 Lunch ()
±³À°½Ã°£ 09-25 Flamingo 13:35~13:50 Metabolic syndrome severity score for predicting cardiovascular events ÇãÁöÇý(ÇѸ²ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09-25 Flamingo 13:50~14:05 Associations between metabolic syndrome and type of dementia ±è¿©Áø(ÃáõÇѸ²´ëº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09-25 Flamingo 14:05~14:20 Metabolic syndrome and incidence of gastric cancer in Korea ±èÇü¼ö(°Ç±¹´ë¿¹¹æÀÇÇаú±³½Ç)
Åä·Ð 09-25 Flamingo 14:20~14:40 Discussion All Panellist()
±³À°½Ã°£ 09-25 Flamingo 14:40~14:55 STRENGTH Trial and its post hoc analysis and cuurent status of EPA ¼ÕÁ¤¿ì(¿øÁÖÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 09-25 Flamingo 14:55~15:10 A Phase2 Trial Of The Efficacy And Safety Of Evinacumab In Patients With Severe Hypertriglyceridemia À念¿ì(°¡ÃµÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 09-25 Flamingo 15:10~15:25 Inpatient Use of Continuous Glucose Monitoring to Improve Hyperglycemia and prevent hypoglycemia ¹Ú¼¼Àº(°ºÏ»ï¼º ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09-25 Flamingo 15:25~15:40 Tracking the CV impact of SGLT-2 inhibitors: A guide to use SGLT2-inhibitors in Clinical Practice È«ÁØÈ(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 09-25 Flamingo 15:40~16:00 Discussion All Panellist()
ÈÞ½Ä 09-25 Flamingo 16:00~16:20 Coffee Break & Photo Time ()
±³À°½Ã°£ 09-25 Flamingo 16:20~16:35 »ýÈ° ¿ä¹ý 1- Èí¿¬, À½ÁÖ, üÁß À̹ÎÈ£(¼øõÇâ ¼¿ïº´¿ø ¼øȯ±â³»°ú)
±³À°½Ã°£ 09-25 Flamingo 16:35~16:50 »ýÈ° ¿ä¹ý 2- ½Ä»ç, ¿îµ¿, ÀÎÁöÇൿ ±èÁöÇý(µ¿±¹´ëº´¿ø ¼øȯ±â³»°ú)
±³À°½Ã°£ 09-25 Flamingo 16:50~17:05 ´ë»çÁõÈıºÀÇ Ç÷¾Ð, ÁöÁú, Ç÷´ç °ü¸® Á¤ÀçÈÆ(±¹¸³ÀÇ·á¿ø ¼øȯ±â³»°ú)
Åä·Ð 09-25 Flamingo 17:05~17:25 Discussion All Panellist()